BridgeBio Pharma Q2 Revenue Beats Estimates

BridgeBio Pharma reported Q2 total revenue of $110.6M, beating estimates of $88M. The company's revenue growth was driven by strong sales of its ATTR-CM treatment, Acoramidis. BridgeBio's revenue exceeded expectations despite a challenging market environment. The company's revenue growth is expected to continue, with analysts predicting further growth in the coming quarters.

BridgeBio Pharma (Nasdaq: BBIO) reported its second-quarter 2025 financial results, showcasing robust revenue growth and a strong cash position. The company's total revenue for the period ended June 30, 2025, reached $110.6 million, significantly surpassing analysts' estimates of $88 million. This performance was primarily driven by the company's flagship drug, Attruby, which generated $71.5 million in U.S. net product revenue, nearly doubling quarter-over-quarter.

Attruby, a transthyretin (TTR) stabilizer for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), has seen accelerating adoption since its FDA approval in November 2024. As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers. The drug's clinical profile was further strengthened by new analyses from the ATTRibute-CM study, demonstrating a 59% relative risk reduction in variant ATTR-CM patients and a 31.6% relative risk reduction in mortality associated with increased TTR stabilization [1].

BridgeBio's diversified revenue streams also contributed to its total revenue, with $1.6 million from royalty revenue and $37.5 million in license and services revenue. The company ended the quarter with a strong cash position of $756.9 million, providing a solid runway for both commercial operations and clinical development.

The company's pipeline continues to advance, with multiple Phase 3 trial results expected in the coming months. The FORTIFY study for BBP-418, an oral glycosylation substrate therapy for limb-girdle muscular dystrophy type 2I/R9, and the CALIBRATE study for encaleret, a calcium-sensing receptor (CaSR) antagonist for autosomal dominant hypocalcemia type 1 (ADH1) and chronic hypoparathyroidism, are expected to deliver topline results in fall 2025. Additionally, PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia, is expected to deliver results in early 2026. These studies represent potential new product launches in 2026-2027, transitioning BridgeBio from a single-product company to a multi-product rare disease leader [1].

Operating expenses increased 37.8% year-over-year to $244.8 million, primarily driven by a $69.6 million increase in selling, general, and administrative expenses (SG&A) reflecting the company's investments in support of the commercial launch and ongoing activities of Attruby. This increase was partially offset by a $3.5 million decrease in research and development expenses (R&D) due to the divestiture of certain assets [1].

BridgeBio's Q2 results demonstrate impressive commercial traction for their ATTR-CM therapy, Attruby, with $71.5 million in U.S. product revenue nearly doubling quarter-over-quarter. The 3,751 unique patient prescriptions from 1,074 prescribers since November 2024 approval signals strong adoption, especially in the treatment-naïve segment where month-over-month growth is accelerating. The company's $110.6 million total quarterly revenue included additional contributions from royalties and milestone payments, highlighting their diversified revenue streams. The $756.9 million cash position provides a solid runway to support both commercial operations and clinical development. What's particularly notable is BridgeBio's maturing pipeline approaching critical inflection points. Three Phase 3 programs - BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia - have completed enrollment with topline readouts expected between fall 2025 and early 2026. These represent potential new product launches in 2026-2027, transitioning BridgeBio from a single-product company to a multi-product rare disease leader. New clinical data strengthens Attruby's competitive positioning, showing a 59% relative risk reduction in variant ATTR-CM patients versus placebo and establishing a direct link between TTR stabilization and mortality reduction. The 43% reduction in cardiovascular hospitalization due to atrial fibrillation/flutter compared to placebo further differentiates the product. While operating expenses increased 37.8% year-over-year to $244.8 million, this reflects planned commercial investment rather than a concern. The launch trajectory and pipeline progress indicate BridgeBio is executing effectively on its genetic disease-focused strategy with multiple potential catalysts ahead. - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total second quarter revenue, comprised of $71.5 million of U.S. Attruby® net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services revenue - Attruby’s differentiated clinical profile was further strengthened by new analyses from the ATTRibute-CM study, reinforcing its position as a potentially best-in-class therapy for ATTR-CM patients: - Statistically significant benefit observed in variant ATTR-CM patients, with a 59% relative risk reduction for time to ACM or first CVH event versus placebo - A 31.6% relative risk reduction in mortality was associated with a 5-mg/dL increase in serum TTR within 28 days of treatment initiation through Month 30, linking early and increased TTR stabilization with improved clinical outcomes - Reduction in annual frequency of CVH due to AF/AFL by 43% compared to placebo and the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - Last participant last visit achieved with topline results from FORTIFY, the registrational Phase 3 study of BBP-418, an oral glycosylation substrate therapy for LGMD2I/R9 expected in fall 2025, supporting an NDA filing for Accelerated Approval in the U.S. - Topline results from CALIBRATE, the registrational Phase 3 study of encaleret for ADH1 expected in fall 2025. Approximately 95% of randomized study participants have already entered the long-term extension of the study - PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia expects topline results in early 2026. Infigratinib has previously demonstrated best-in-class improvements in annualized height velocity and upper-to-lower body proportionality and was granted Breakthrough Therapy Designation by the FDA - The Company ended the quarter with $756.9 million in cash, cash equivalents and marketable securities, well capitalized to continue executing on the Attruby launch and to deliver topline results from key Phase 3 trials - Earnings call followed by question-and-answer period for the analyst and institutional investor community today, August 5th at 4:30 pm ET PALO ALTO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided business updates. Commercial Progress: As of August 1, 2025, 3,751 unique patient prescriptions for Attruby have been written by 1,074 unique healthcare providers since FDA approval in November 2024. The second quarter revenue totaled $110.6 million , comprised of $71.5 million of U.S. Attruby net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services revenue. “Attruby’s latest results showcase the power of pairing breakthrough scientific excellence with disciplined commercial execution,” said Matt Outten, Chief Commercial Officer of BridgeBio. “Product revenue nearly doubled this quarter, driven by growing adoption across centers of excellence and community physicians. With increasing demand and best-in-class patient access programs, we are confident Attruby will become the standard of care for ATTR-CM, setting the foundation for three additional rare disease launches in 2026 and 2027.” Pipeline Overview: Key Program Updates: “The launch of Attruby continues to accelerate, increasing the number of patients’ lives we are able to touch. We remain grateful for the physicians and patients who are partnering with us on both treatment and on new clinical research,” said Neil Kumar, Ph.D., CEO and Founder of BridgeBio. “The next six months will be transformative with Phase 3 readouts across ADH1, LGMD2I/R9, and achondroplasia. We hope these programs will build on Attruby’s success to allow us to become a leading diversified genetic disease company.” Attruby (acoramidis) – First near-complete (≥ 90% ) transthyretin (TTR) stabilizer for